Brief: Advicenne Announces FDA Clearance Of IND To Commence Pivotal Phase 3 Trial Of Adv7103
05/09/2018 16:49
Sept 5 (Reuters) - Advicenne SA ADVIC.PA :
* ADVICENNE ANNOUNCES FDA CLEARANCE OF IND TO COMMENCE
PIVOTAL
PHASE 3 TRIAL OF ADV7103 FOR DISTAL RENAL TUBULAR ACIDOSIS
* ADVICENNE SA - U.S. FDA CLEARED IND APPLICATION FOR
ADV7103,
ALLOWING CO TO FORMALLY INITIATE ARENA-2 PIVOTAL PHASE 3 TRIAL
Source text for Eikon: ID:nBw8vWlsFa
Further company coverage: ADVIC.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Advicenne SA
See all newsBrief: Advicenne Secures Cash Runway To Q2 2027 Through Bond Financing Of Amount Of Up To €3.8 Mln
Corrected: BRIEF-Advicenne FY Net Income EUR -9.532 Million (March 26)
France's Advicenne 2025 sales rise, net loss widens
Brief: Advicenne FY Net Income EUR -9.532 Million
Brief: Advicenne SA -Cash Position Of EUR 2.0 Million With Unchanged Financial Visibility In Q1 2025